{
    "clinical_study": {
        "@rank": "104215", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Dose 1 of REGN1908-1909 or placebo"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Dose 2 of REGN1908-1909 or placebo"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Dose 3 of REGN1908-1909 or placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the safety and tolerability of  single\n      ascending doses of subcutaneously (SC) administered  REGN1908-1909 in allergic, adult\n      subjects."
        }, 
        "brief_title": "Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy men and women between the ages of 18 and 55\n\n          2. Positive allergen skin prick test\n\n          3. Willing and able to comply with clinic visits and study-related procedures\n\n          4. Provide signed informed consent\n\n        Exclusion Criteria:\n\n          1. Persistent, chronic, or active recurring infection requiring treatment with\n             antibiotics,  antivirals, or antifungals within 4 weeks prior to the screening visit\n\n          2. Any clinically significant (determined at the investigator's discretion)\n             abnormalities  observed during the screening physical examination\n\n          3. Onset of a new exercise routine or major change to a previous exercise routine within\n              4 weeks prior to the screening visit. Patients must be willing to maintain a similar\n             level  of exercise for the duration of the study and to refrain from unusually\n             strenuous exercise  for the duration of the trial\n\n          4. Hospitalization for any reason within 60 days prior to the screening visit\n\n          5. Participation in any clinical research study evaluating another investigational drug\n             or  therapy within 30 days or at least 5 half-lives (whichever is longer) of the\n             investigational drug prior to the screening visit\n\n          6. Any medical or psychiatric condition that in the opinion of the investigator or\n             Regeneron,  would place the patient at risk, interfere with participation in the\n             study or interfere with  the interpretation of study results\n\n        The information listed above is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial and not all inclusion/ exclusion\n        criteria are listed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922661", 
            "org_study_id": "R1908-HV-1240"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "intervention_name": "REGN1908-1909", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is to assess treatment-emergent adverse events (TEAEs) from day 1 through day 113 (end of study).", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "day 1 to day 113"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922661"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary endpoint is serum concentrations of REGN1908-1909 over time.", 
            "measure": "Serum concentration", 
            "safety_issue": "No", 
            "time_frame": "day 1 to day 113"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}